Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
23.00    0.00 (0.00%)
Bid:
22.00
Ask:
24.00
Spread: 2.00 (9.091%)
Market Cap: £31.87m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Additional disclosure concerning Michael Owen

29 Jul 2019 16:29

RNS Number : 0933H
Sareum Holdings PLC
29 July 2019
 

(AIM: SAR)

29 July 2019

 

Sareum Holdings plc

("Sareum" or "the Company")

Additional disclosure concerning Michael Owen

 

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS ("BliNK") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.

 

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Nominated Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7638 9571

 

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNEKLFLKDFLBBQ
Date   Source Headline
30th Sep 20224:36 pmRNSPrice Monitoring Extension
12th Sep 20227:00 amRNSSareum notes FDA approval of first TYK2 Inhibitor
28th Jul 20227:00 amRNSCTA application to MHRA and Corporate Update
4th Jul 20227:00 amRNSSareum notes GSK's completed acquisition of Sierra
26th Apr 20227:00 amRNSSareum to Present at BioTrinity 2022 Conference
13th Apr 20224:00 pmRNSSareum notes acquisition of Sierra Oncology by GSK
13th Apr 202211:05 amRNSSecond Price Monitoring Extn
13th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSEuropean Patent Granted for Sareum’s SDC-1802
8th Apr 20224:41 pmRNSSecond Price Monitoring Extn
8th Apr 20224:36 pmRNSPrice Monitoring Extension
6th Apr 20222:06 pmRNSSecond Price Monitoring Extn
6th Apr 20222:00 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSSDC-1801: Preclinical Toxicology Report Received
9th Mar 202211:06 amRNSSecond Price Monitoring Extn
9th Mar 202211:00 amRNSPrice Monitoring Extension
28th Feb 20223:50 pmRNSResults of EGM
21st Feb 20227:00 amRNSHalf-year Report
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSPublication of Circular; Notice of General Meeting
28th Jan 20228:11 amRNSCorrection - Issue of Warrants
28th Jan 20227:00 amRNSIssue of Warrants
25th Jan 20227:00 amRNSSareum to Participate in Edison Open House Event
17th Dec 20217:00 amRNSSubscription to raise £1.63m to progress SDC-1801
16th Dec 20214:21 pmRNSResult of AGM
16th Dec 20217:00 amRNSAGM Statement
15th Dec 20217:00 amRNSIntention to grant notice - EU patent for SDC-1802
7th Dec 20217:00 amRNSAGM Update
23rd Nov 202112:57 pmRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSNotice of AGM
3rd Nov 20213:00 pmRNSExercise of Share Options and Director Dealings
29th Oct 20217:00 amRNSAppointment of Joint Corporate Broker
25th Oct 20217:00 amRNSSareum: Final Results for Year Ended 30 June 2021
21st Oct 20218:32 amRNSCorrection - Notice of Results
21st Oct 20217:00 amRNSNotice of Results and Investor Presentation
7th Oct 202110:42 amRNSUS Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
29th Sep 202110:46 amRNSReference to SRA737 Timeline at Cantor Conference
19th Aug 20217:00 amRNSTrading Statement
9th Aug 20211:26 pmRNSSubscription to raise £1,000,000
6th Aug 20217:19 amRNSSRA737 update
30th Jul 20217:00 amRNSUS Patent Notice of Allowance for SDC-1802
19th Jul 20212:05 pmRNSSecond Price Monitoring Extn
19th Jul 20212:01 pmRNSPrice Monitoring Extension
19th Jul 202111:13 amRNSSubscription to raise £1,000,000
14th Jul 20217:00 amRNSExercise of Warrants and Total Voting Rights
1st Jul 20217:00 amRNSCovid-19 Research Project Results
24th Jun 20212:05 pmRNSSecond Price Monitoring Extn
24th Jun 20212:00 pmRNSPrice Monitoring Extension
21st Jun 20218:00 amRNSSareum to Present at BioTrinity 2021 Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.